BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Biocity Biopharmaceutics Co., Ltd., now recruiting.
Overview
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07469774 by Biocity Biopharmaceutics Co., Ltd., with 111 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: BC3195 and Pembrolizumab/KEYTRUDA®.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.